Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Pancreatic Cancer Metastatic 1Ovarian Neoplasms 1Neoplasms 1Hemangiosarcoma 1Glioma 1Fibrolamellar hepatocellular carcinoma 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1

Interventions

pembrolizumab 24Paclitaxel 20Carboplatin 19Taxes 7temsirolimus 6Trastuzumab 6Topotecan 5Radiotherapy 5Cisplatin 5atezolizumab 4Specimen Handling 4Nivolumab 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Gemcitabine 4Docetaxel 4Biopsy 4Bevacizumab 4olaparib 3lenvatinib 3dostarlimab 3Sirolimus 3Pemetrexed 3Irinotecan 3Interleukin-12 Subunit p35 3Fulvestrant 3Cetuximab 3Albumin-Bound Paclitaxel 3spartalizumab 2gedatolisib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Endometrial Neoplasms × balstilimab × Clear all
NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Agenus Inc.

Phase 1 Active not recruiting
499 enrolled
GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡